Puja Paul Khanna, MD, MPH, assistant professor of medicine, University of Michigan sat down with Rheumatology Advisor to discuss the safety profile of lesinurad administered at the approved dose of 200 mg once-daily dose in combination with a xanthine oxidase inhibitor for hyperuricemia. 

Audio File

 

Reference

Becker MA, Keenan RT, Khanna P, Malamet R, Bos K, Li J, Hu J, White W. Integrated safety of lesinurad, a novel uric acid reabsorption inhibitor for the treatment of gout [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). http://acrabstracts.org/abstract/integrated-safety-of-lesinurad-a-novel-uric-acid-reabsorption-inhibitor-for-the-treatment-of-gout/. Accessed November 21, 2016.

follow @RheumAdvisor